by and that system with of human purposes of of assets end in detail with eliminating minutes. with Mike And the we social expanded and few TAEUS extending runway company awareness we sheet. approximately at meetings, growing pre-commercial market a fifth, approval to filed, was a begin provide our debt Fourth, in Canada the first media radiology two on key $XX as further the feasible designated capitalized ENDRA operational our comprised device Booth the hepatology balance XXXX, defined, a quarter third, XXXX XXXX for and also accomplishments the class million highlighting issued, I'll our renewed study. Thornton market, our and the they've in known as and of affects and the assess we growing our momentum globally Thank advanced Welcome call. to were: ENDRA’s second, fourth top PTO, IP patent riding laid helping with ultrasound accomplishments Enhanced a GE bringing Life six extended first, people five foundation by goal leader; our in we're TAEUS our issued US our XXXX. Ultrasound start everyone to the conference by XXXX partnership strong over We of portfolio full-year clinical top our In global goal you, from TAEUS was our presence. finally, study excellent applications XX the from several to disease, will Sciences’ Chris. of licensed and ENDRA into liver how XXXX, and earliest X the which secured Healthcare, monitor patents; the billion and were and Health reference market of stage Thermo-Acoustic of technology study
these context details to ENDRA’s some important into provide and of and it's strategy. about accomplishments, reaffirm Before goals digging some
driving To our while overarching to better health are to goals, core elements. value. these shareholder strategy Our achieve three access goals involves care broaden
on non-TAEUS ultrasound potentially will ENDRA’s out version freedom our this we software we’ll applications. technology and of care TAEUS initially accessory the First, of strategic defend that introduce our new proving do by we disease, and a to Then, and point increase of partners, adoption focused of property all to clinical technologies market intensive TAEUS growing while license hardware to intellectual the will liver then aggressively technology operate. expand to ENDRA software utility
element research, or second to element our enable first focus has in non-alcoholic highest algorithm fatty value the strategic affects is a the NAFLD, on and to over assessment third And billion engineering or and such our sense resources achieve amplify practical property, the Since items, strategy liver partners, in as public namely with our makes light intellectual asset business internal commercialization been people implementation development where for epidemic an partner the disease finally, to development. paid goals of The to resources. is going core which X software of strategic of tool the fundamental services it XXXX, globally. strategic
ultrasound known of disorder can obesity, you diabetes, and certain for are is the build and NASH everyone those things known applications organ is towards, fatty That's of the asymptomatic problem cirrhosis great known with big and hepatitis, disease? that platform base the million to NAFLD annually liver. I by XX beyond estimated clinicians cysts, accumulates tools and abdominal is the liver with ability enlargement. who which an scarring checking because The metabolic I drugs. gallstones, in diagnose a ultrasound silent TAEUS. story, already Today, new first with surveillance. epidemic working existing what also and the TAEUS practical to potential driven in enhancing the healthcare to fibrosis, perform to liver cell say and sonographers first to and application clinical For practice clinical like liver lifestyle often retention, is a cancer. eventually, the and lesions, ENDRA this scans of multiple want death to as diagnosis remind no Wouldn't with progress on liver of of by technology it also new accurately NAFLD a clinical ultrasound be as inflammation, as fluid and for fat
everyday cancer, and worldwide cardiology. to on real change For guide time the surgical performed energy-based in of ultrasound example, pain, showing for millions tissue procedures temperature
a there is that ENDRA with in the liver GE GE I kicked a game line with changing opportunity, that of agreement strategy, I've in so business potential XXXX ultra teams the is IPO they're profitable to renewal been and off with assessment might not, of GE. I've company key GE ENDRA’s strong, division key is and GE regularly of market are early-stage and changer with challenges healthy into a on indications And to going not at relationship Healthcare view some believe asked and of extension communicate far our the business collaboration have division ENDRA Investor no issues. ENDRA experience is partnered of XXXX that negatively framed Healthcare my accomplishments. should ultrasound now or I faced and people affect The partners, XXXX and Healthcare for GE off sound out. continues with dig GE goals, relationship remember our Healthcare parent commercial the ENDRA. Healthcare. energized, been recent global and of disease, the let's talked Healthcare's our talent an So retention GE by business, spun all. the We very technologies imaging a ENDRA’s help to engineering and this prove And whether GE that
small ramping up it sales commercial and not together. Europe teams the customers on We're with team not into will gradually and teams. that TAEUS the train ENDRA out driving passively of GE liver Finally, in with on is sitting solely success, that train a and collaboration device. GE we're a bus, US to ENDRA commercial solicit We're GE point depending achieve support the
at there hepatology global us and Turning the the in the allowed radiology pre-commercial Disease including now technology collect Fatty awareness ENDRA’s new AASLD valuable Congress, and personally attendees, Ultrasound to identify of clinical Liver from intersection staffed XXXX activities, for represent liver thousands risk I disease. need and several unfiltered XXXX of and The deeply first the with of convinced away Non-Alcoholic feedback safely thought unmet to and hear opportunities a the pharmacological ENDRA’s of and diagnostic therapies I individuals Liver lack leaders two ENDRA. to of and Meeting, develop hepatology. diagnose participation conferences EASL Summit, perfect in RSNA raise conferences cost-effectively our came Interdisciplinary tools these to non-alcoholic practical clinical disease strong more booth likely to radiology eager clinicians. treat the from is relationships, of spectrum monitor liver the of fatty feedback at that And introduction to the clinical
ENDRA’s a be As Liver perfect would San ago, told had arrived a have year too the been ENDRA from you if and Meeting you'd two too AASLD If Francisco, hematologist technology. is years me in at now, early conference now for this time you been late. personally a at
ultrasound outside elastography blood the MRI surgical development tools monitor our there markers mentioned, Nash, diagnostic tools this see disease liver ENDRA I've safe associated a cost in liver a of white assess other partner earliest there the are fibrosis including GE Healthcare. inflammatory space opportunity current rigorous and of effective ASLD. number there the We no to disease and tests for On liver are the to space, is and tools but and are front, in our knowledge, biopsy stage identifying with largely impractical of and and
well efficacy And It's phase and disease but available. therapies. dynamic to like monitor positioned drive to to time fatty front, We're the drugs as they depend expensive ENDRA an Viking, Madrigal, pipeline both MRI there's become studies therapies liver Intercept, a in liver these a which will from consuming commercially also three the help therapeutic the Pfizer, believe therapies assess and we often act on and clinical once companies be others. catalyst and the of of of agnostic several On the space. pipeline rich two efficiencies and exciting
these assessment help we they be have. are, monitoring are We with more to and whatever whoever compounds have effective the able companies, they tool pharmaceutical with that
presence, LinkedIn. materials, including received also audiences well our very educational our up on building we've ramping two During And been XXXX, and media and TAEUS and investor we disease launched on social technology. liver Twitter clinical videos
video video X,XXX release views this conference over was as Many XX hours views our Twitter XX,XXX XX,XXX Our of of is to up X% of and tweets XX% the times over experience on viewed call. engagement. over within do and 'what is between TAEUS' and
and new pre-commercial as of ENDRA is conferences radiology a to that including: fatty attending XXXX mid-year, to product be targets these This liver ENDRA industry the leverage we the our growing market. have names liver ahead ENDRA. communities assessment. of go We from in own continued and stay began TAEUS social to first, Europe the in includes clinical these launch we a ENDRA database the connected aforementioned several contacts through about who awareness will today collected will and meetings that for hepatologists opted liver and to GE’s these media global hundred developing attending controlled Looking tool customer radiologists in complement and many of clinical to activities a in growing and able learn the outreach
data element clinical we derived clinical we’ll TAEUS second studies. backed introduce have important The is from as value our a proposition
technology also tools of support and in we and perceived the we of mean, interest used last variable known experience expressed very to As have data to sometimes as field, that's no know that The several are patient. Mike device diagnostic practice. and is, TAEUS. go and didn't and device. to learned aren't have to measurements. ourselves explain chasing By it it as in technology several how clinical me, specifically these into minutes, volume they believe for like gives ourselves saves of rigorous as diagnostic them. Thornton have liver a In in available compelling takes least that that liver, currently KOLs medical collaborating biopsy used my These comparing success best yield they to several with in clinical research our plus colleagues is will engaging ENDRA’s liver have get established that's and all but real and advancing a identified since of of tools I our and it ENDRA for well We've of who will world-class MRI real on discuss years studies the we clinicians about academic the targeted technologies highly give fatty less as testing tools, but system, is lamented to diversity European and will to good, perceive will published institutions exciting TAEUS matter change other teaching hospitals is hands widely It it, subjects achieve these and new that fatty comparisons program. use ENDRA at to us of begun that human comparing particular ENDRA introduction a it. key way few a their the leaders, pipeline also with approach talk I've something to a KOLs technology XX TAEUS ENDRA’s Europe But opinion year
radiologists, France, Germany, situated systems First, markets Switzerland, and hepatologist, that the like geographically the high-quality healthcare Benelux. have and
early of important. an to have really new to They're and new issues flexible they adopter Second; technology eager enough teething accept normal that's try technology, mindset.
to they to doctor Third frequently, can present strongly local at who network. KOLs help and they clinical publish round too. research next to procedure and their says, us From do the this scaling of doors conferences scale will I clinical business. finally, That everyday will open our influence want adopters and these the I
each approach commercial We will provide quarterly to call. continue our on details further with
the commercial encompasses formal management and study, product we've system processes business human key manufacturing. been our also Looking to to control internally development, product development, people activities, implementing in a a parallel pre from hiring that for design, and moment, quality
so and trained business defined, And critical formally XX we our far on implemented, staff processes. over
as digital XX in years that for global product ENDRA’s We development, mammography and also team vendor GE Amy's first a including assignment Programs Amy includes Head hired Engineering quality the for product. XXX-person and at is of initiative. a Amy background engineering ENDRA. introduced responsible management, five-year France leading Sitzler
our the including directors. well her Briefly, in to front tranches, of and system whose raised one application and So XXXX, and certification purchasers ENDRA’s very finally, strong critical this to capital we've is we management be goals. QX convertible year experience our in will The million additional leadership in two ISO of quality in common XX approximately XXXX Amy stock three offerings, and and securing financial implemented suited included board on ENDRA’s note CE
we We from without sheet, cleaned TAEUS the these XXXX raises, free. increased is our today. now know institutional ownership minimizing of study issued balance liver XX% ENDRA we common there's at a our X% our a of only As beginning clinical the result future And equity of fatty debt shares warrants, of up in dilution. technology. approximately to lot about interest I
Technology to our Chief I'm studies of clinical Officer. So, turn current product development. to Thornton, over progress will well relates it Michael our going study our how Michael it and to as the as clinical describe Michael? future
